ReviewMicrobiology spectrum2017
Treatment of Latent Tuberculosis Infection.
Review in Microbiology spectrum, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 3 syntheses or guidelines pooled it, 33 citations in OpenAlex.
- Effective mHealth interventions to improve tuberculosis treatment adherence in Asia: a systematic review and meta-analysis.BMC public health · 2026Pooled it
- The potential use of rifabutin for treatment of patients diagnosed with rifampicin-resistant tuberculosis.The Journal of antimicrobial chemotherapy · 2018Pooled it
- Isoniazid-Rifapentine for Latent Tuberculosis Infection: A Systematic Review and Meta-analysis.American journal of preventive medicine · 2018Pooled it
- Breaking barriers: Implementation of a tuberculosis preventive treatment protocol among newly eligible populations with promising results.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2026Article
- The outcomes of isoniazid prophylaxis in LTBI high-risk pediatric patients undergoing hematopoietic stem cell transplantation.BMC infectious diseases · 2026Article
- Psoriasis flare confused with drug allergy: A collaborative effort is required to treat tuberculosis in the setting of severe psoriasis.Respiratory medicine case reports · 2026Article
- Should miliary tuberculosis be considered as a possible cause of infertility in the new era: a case report and literature review.Frontiers in medicine · 2025Article
- Incipient tuberculosis: a comprehensive overview.Infection · 2024Review
- Isoniazid and rifapentine treatment effectively reduces persistent M. tuberculosis infection in macaque lungs.The Journal of clinical investigation · 2022Article
- Review
- The Biological and Clinical Aspects of a Latent Tuberculosis Infection.Tropical medicine and infectious disease · 2022Review
- [Treatment of ocular tuberculosis-an update].Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft · 2020Review
- Isoniazid and Rifapentine Treatment Eradicates PersistentAmerican journal of respiratory and critical care medicine · 2020Article
- Latent Tuberculosis Infection among Healthcare Students and Postgraduates in a Mediterranean Italian Area: What Correlation with Work Exposure?International journal of environmental research and public health · 2019Article
- Evaluation of Standard E TB-Feron Enzyme-Linked Immunosorbent Assay for Diagnosis of Latent Tuberculosis Infection in Health Care Workers.Journal of clinical microbiology · 2019Article
- Latent tuberculosis infection in patients with rheumatic diseases.Jornal brasileiro de pneumologia : publicacao oficial da Sociedade Brasileira de Pneumologia e Tisilogia · 2019Review
- Skin microbiota-host interactions.Nature · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
There are approximately 56 million people who harbor Mycobacterium tuberculosis that may progress to active tuberculosis (TB) at some point in their lives. Modeling studies suggest that if only 8% of these individuals with latent TB infection (LTBI) were treated annually, overall global incidence would be 14-fold lower by 2050 compared to incidence in 2013, even in the absence of additional TB control measures. This highlights the importance of identifying and treating latently infected individuals, and that this intervention must be scaled up to achieve the goals of the Global End TB Strategy. The efficacy of LTBI treatment is well established, and the most commonly used regimen is 9 months of daily self-administered isoniazid. However, its use has been hindered by limited provider awareness of the benefits, concern about potential side effects such as hepatotoxicity, and low rates of treatment completion. There is increasing evidence that shorter rifamycin-based regimens are as effective, better tolerated, and more likely to be completed compared to isoniazid. Such regimens include four months of daily self-administered rifampin monotherapy, three months of once weekly directly observed isoniazid-rifapentine, and three months of daily self-administered isoniazid-rifampin. The success of LTBI treatment to prevent additional TB disease relies upon choosing an appropriate regimen individualized to the patient, monitoring for potential adverse clinical events, and utilizing strategies to promote adherence. Safer, more cost-effective, and more easily completed regimens are needed and should be combined with interventions to better identify, engage, and retain high-risk individuals across the cascade from diagnosis through treatment completion of LTBI.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.